Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Afatinib in EGFR-Mutant NSCLC
NCT02364609Phase 1Completed
- Start
- Sep 2015
- Primary completion
- Apr 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoint: Maximum Tolerated Dose at Day 21. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02364609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02364609.